ATE477251T1 - Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren - Google Patents
Pyrrolverbindungen als glykogen synthase kinase 3 inhibitorenInfo
- Publication number
- ATE477251T1 ATE477251T1 AT03749133T AT03749133T ATE477251T1 AT E477251 T1 ATE477251 T1 AT E477251T1 AT 03749133 T AT03749133 T AT 03749133T AT 03749133 T AT03749133 T AT 03749133T AT E477251 T1 ATE477251 T1 AT E477251T1
- Authority
- AT
- Austria
- Prior art keywords
- gsk3
- glycogen synthase
- synthase kinase
- disorders
- inhibitors
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 title 1
- 108091007911 GSKs Proteins 0.000 abstract 4
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40584602P | 2002-08-23 | 2002-08-23 | |
| PCT/US2003/026625 WO2004018455A1 (en) | 2002-08-23 | 2003-08-21 | Pyrrole based inhibitors of glycogen synthase kinase 3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE477251T1 true ATE477251T1 (de) | 2010-08-15 |
Family
ID=31946938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03749133T ATE477251T1 (de) | 2002-08-23 | 2003-08-21 | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7250443B2 (de) |
| EP (1) | EP1537099B1 (de) |
| JP (1) | JP2006501243A (de) |
| KR (1) | KR20050038631A (de) |
| CN (1) | CN1688573A (de) |
| AT (1) | ATE477251T1 (de) |
| AU (1) | AU2003268184A1 (de) |
| CA (1) | CA2496246A1 (de) |
| DE (1) | DE60333762D1 (de) |
| TW (1) | TW200413352A (de) |
| WO (1) | WO2004018455A1 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0174535B1 (ko) * | 1989-09-04 | 1999-02-01 | 알렌 제이 스피글 | 베타-락탐 함유 화합물 및 그의 제조방법 |
| EP1568698A1 (de) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrolderivate als faktor-xa-inhibitoren |
| WO2006034207A2 (en) * | 2004-09-17 | 2006-03-30 | Vanderbilt University | Use of gsk3 inhibitors in combination with radiation therapies |
| US20060204980A1 (en) * | 2004-12-28 | 2006-09-14 | Altieri Dario C | Colorectal cancer therapies |
| SI1858920T1 (sl) | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
| NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
| JP2009501546A (ja) | 2005-07-18 | 2009-01-22 | ノバルティス アーゲー | Ｈｃｖ複製についての小動物モデル |
| CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
| PL1951299T3 (pl) | 2005-11-04 | 2012-07-31 | Novartis Ag | Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność |
| PL1945252T3 (pl) | 2005-11-04 | 2013-11-29 | Seqirus Uk Ltd | Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant |
| US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| KR20080089663A (ko) | 2006-01-27 | 2008-10-07 | 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
| SG173336A1 (en) | 2006-03-31 | 2011-08-29 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| DE102006027229A1 (de) * | 2006-06-09 | 2007-12-20 | Grünenthal GmbH | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP2586790A3 (de) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogene von uropathogenen Escherichia coli |
| WO2008032219A2 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
| CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| HRP20120790T1 (hr) | 2007-06-27 | 2013-01-31 | Novartis Ag | Cjepiva protiv influence sa niskom koliäśinom aditiva |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| ES2535101T3 (es) | 2008-03-18 | 2015-05-05 | Novartis Ag | Mejoras en la preparación de antígenos en vacuna de virus de la gripe |
| MY161598A (en) * | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| CN102438650A (zh) | 2009-03-06 | 2012-05-02 | 诺华有限公司 | 衣原体抗原 |
| WO2010119343A2 (en) | 2009-04-14 | 2010-10-21 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| CA2763816A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Adjuvanted vaccines for protecting against influenza |
| AU2010245072B2 (en) * | 2009-05-05 | 2013-11-28 | Merck Sharp & Dohme Corp. | p38 kinase inhibiting agents |
| ES2662716T3 (es) | 2009-07-07 | 2018-04-09 | Glaxosmithkline Biologicals Sa | Inmunógenos conservados de Escherichia coli |
| PL3178490T3 (pl) | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Kompozycje białka f rsv i sposoby ich wytwarzania |
| AU2010272243A1 (en) | 2009-07-16 | 2012-03-08 | Novartis Ag | Detoxified Escherichia coli immunogens |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| ME02800B (de) * | 2009-12-01 | 2018-01-20 | Abbvie Inc | Neue trizyklische verbindungen |
| JP5781542B2 (ja) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原 |
| JP2013532008A (ja) | 2010-05-28 | 2013-08-15 | テトリス オンライン インコーポレイテッド | 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
| ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
| EP2729178A1 (de) | 2011-07-08 | 2014-05-14 | Novartis AG | Tyrosinverbindungsverfahren |
| EP2554662A1 (de) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Verfahren zur Behandlung von Netzhautdegenerationserkrankungen |
| US9493517B2 (en) | 2011-11-07 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Conjugates comprising an antigen and a carrier molecule |
| BR112014016548A8 (pt) | 2012-01-06 | 2017-07-04 | Board Of Regents Of The Univ Of Oklahoma | tensoativos baseados em sulfóxido |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| CA2885625A1 (en) | 2012-10-02 | 2014-04-10 | Glaxosmithkline Biologicals S.A. | Nonlinear saccharide conjugates |
| SMT201800011T1 (it) | 2012-11-30 | 2018-05-02 | Glaxosmithkline Biologicals Sa | Antigeni e combinazioni di antigeni di pseudomonas |
| EP2870974A1 (de) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella-Konjugatimpfstoffe |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US10031153B2 (en) | 2014-06-27 | 2018-07-24 | Schlumberger Technology Corporation | Magnetic ranging to an AC source while rotating |
| US10094850B2 (en) | 2014-06-27 | 2018-10-09 | Schlumberger Technology Corporation | Magnetic ranging while rotating |
| AU2015361018B2 (en) | 2014-12-08 | 2020-01-16 | Fmc Corporation | 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10227551B2 (en) | 2015-11-12 | 2019-03-12 | Novus International, Inc. | Sulfur-containing compounds as solvents |
| EP3231434A1 (de) | 2016-04-14 | 2017-10-18 | Fundacio Centre de Regulacio Genomica | Verfahren zur behandlung von parkinsonismus |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| WO2025066935A1 (en) * | 2023-09-28 | 2025-04-03 | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | Compounds, compositions and methods thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2488336A (en) | 1947-07-09 | 1949-11-15 | Du Pont | Production of nu-alkyl pyrroles |
| DE1445762A1 (de) | 1964-04-29 | 1969-01-16 | Bayer Ag | Verfahren zur Herstellung von Chinonderivaten |
| US3534061A (en) | 1967-12-04 | 1970-10-13 | Parke Davis & Co | N-(alpha-(p-methoxyphenyl)-beta-nitrostyryl)-phenoxyalkyl pyrroles |
| JPH0681752B2 (ja) * | 1986-04-02 | 1994-10-19 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| US4985560A (en) * | 1990-01-12 | 1991-01-15 | American Home Products Corporation | Pyridazino(4,5-b)indolizines |
| US5376668A (en) * | 1990-08-21 | 1994-12-27 | Novo Nordisk A/S | Heterocyclic compounds |
| AU7692696A (en) * | 1995-12-01 | 1997-06-27 | Novartis Ag | Heteroaryl derivatives |
| CN1312807A (zh) * | 1998-06-19 | 2001-09-12 | 希龙公司 | 糖元合成酶激酶3的抑制剂 |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| CN1272328C (zh) | 1999-12-17 | 2006-08-30 | 希龙公司 | 糖元合成酶激酶3的基于吡嗪的抑制剂 |
| EP1240168B1 (de) * | 1999-12-17 | 2005-08-31 | Chiron Corporation | Bizyklische inhibitoren von glycogen synthase kinase 3 |
| CN1266129C (zh) * | 2000-01-19 | 2006-07-26 | 卡地拉健康护理有限公司 | 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物 |
| MXPA02008801A (es) * | 2000-03-09 | 2003-07-07 | Ono Pharmaceutical Co | Derivados de indol, proceso para la preparacion de los mismos y su uso. |
| AU2001258784A1 (en) * | 2000-05-22 | 2001-12-03 | Takeda Chemical Industries Ltd. | Tyrosine phosphatase inhibitors |
-
2003
- 2003-08-21 AT AT03749133T patent/ATE477251T1/de not_active IP Right Cessation
- 2003-08-21 DE DE60333762T patent/DE60333762D1/de not_active Expired - Lifetime
- 2003-08-21 CN CNA038243350A patent/CN1688573A/zh active Pending
- 2003-08-21 AU AU2003268184A patent/AU2003268184A1/en not_active Abandoned
- 2003-08-21 JP JP2004531200A patent/JP2006501243A/ja not_active Ceased
- 2003-08-21 KR KR1020057003094A patent/KR20050038631A/ko not_active Ceased
- 2003-08-21 US US10/646,625 patent/US7250443B2/en not_active Expired - Fee Related
- 2003-08-21 WO PCT/US2003/026625 patent/WO2004018455A1/en not_active Ceased
- 2003-08-21 EP EP03749133A patent/EP1537099B1/de not_active Expired - Lifetime
- 2003-08-21 CA CA002496246A patent/CA2496246A1/en not_active Abandoned
- 2003-08-22 TW TW092123152A patent/TW200413352A/zh unknown
-
2007
- 2007-06-12 US US11/761,937 patent/US7671049B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1688573A (zh) | 2005-10-26 |
| US7671049B2 (en) | 2010-03-02 |
| CA2496246A1 (en) | 2004-03-04 |
| US20040077707A1 (en) | 2004-04-22 |
| JP2006501243A (ja) | 2006-01-12 |
| DE60333762D1 (de) | 2010-09-23 |
| EP1537099B1 (de) | 2010-08-11 |
| WO2004018455A1 (en) | 2004-03-04 |
| AU2003268184A1 (en) | 2004-03-11 |
| TW200413352A (en) | 2004-08-01 |
| KR20050038631A (ko) | 2005-04-27 |
| US7250443B2 (en) | 2007-07-31 |
| EP1537099A1 (de) | 2005-06-08 |
| US20070244109A1 (en) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE477251T1 (de) | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren | |
| ATE303383T1 (de) | Bizyklische inhibitoren von glycogen synthase kinase 3 | |
| DE60037905D1 (de) | Pyrazin-basierte hemmer der glycogen-synthase-kinase 3 | |
| ATE274510T1 (de) | Glycogen synthase kinase 3 inhibitoren | |
| WO2002020495A3 (en) | Inhibitors of glycogen synthase kinase 3 | |
| WO2007041365A3 (en) | 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | |
| CL2007001734A1 (es) | Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras. | |
| ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
| TNSN06315A1 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes | |
| TNSN07161A1 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| DE602004024572D1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| MXPA04002982A (es) | Derivados de pirrolidinona. | |
| TW200607803A (en) | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | |
| WO2007127474A3 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| MX2007011848A (es) | Antagonistas del receptor de procineticina i. | |
| MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
| MXPA05003718A (es) | Compuestos x-nitro, sus composiciones farmaceuticas y sus usos. | |
| GB0519760D0 (en) | Novel compounds | |
| WO2005112923A3 (en) | 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes | |
| NO20042138L (no) | Forbindelser og fremgangsmate for behandling av hyperaktiv blaere | |
| DK1931735T3 (da) | Texaphyrinmetalkomplekser med høj renhed | |
| DE602004010186D1 (de) | Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |